New Mexico PA Busted: DEA Yanks Controlled Substance Privileges
Published Date: 7/9/2025
Notice
Summary
John Hanley, P.A. from New Mexico lost his DEA registration because he no longer has the state permission to handle controlled substances. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his certificate starting in 2025. This means John can’t legally prescribe or manage controlled drugs anymore, affecting his medical practice and patients.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA registration revoked for John Hanley
The Drug Enforcement Administration revoked Certificate of Registration No. MH4317702 issued to John Hanley, P.A. The Order states his New Mexico physician assistant license was revoked on or about February 27, 2024, and the DEA revocation is effective August 8, 2025.
Pending renewals and new registrations denied
The Order also denies any pending applications by John Hanley, P.A. to renew or modify Certificate No. MH4317702 and denies any other pending application by him for additional registration in New Mexico. The denial is part of the same final Order effective August 8, 2025.
15-day window to seek reconsideration
The Agency states that John Hanley may file a properly supported motion for reconsideration of the findings of fact within fifteen calendar days of the date of this Order. Any such motion and response must be filed and served by email as directed in the Order.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-12700 — Information Collection Being Reviewed by the Federal Communications Commission Under Delegated Authority
The FCC is asking the public and other agencies to help review and improve its paperwork rules to make things easier and clearer for everyone, especially small businesses. They want to make sure the info they collect is useful and not too much of a hassle. This is a chance to share ideas before any changes happen, so keep an eye out and speak up!
Next: 2025-12702 — Andrew Jones, M.D.; Decision and Order
Dr. Andrew Jones from Texas lost his state permission to handle controlled substances, so the DEA has officially taken away his registrations to prescribe or manage these drugs. This means he can no longer legally work with controlled substances in Texas, effective immediately. If you’re a patient or partner, this change affects how controlled meds are handled starting now, with no money or license privileges for Dr. Jones.